CLINICAL TRIALS PROFILE FOR HYDROCORTISONE; UREA
✉ Email this page to a colleague
505(b)(2) Clinical Trials for HYDROCORTISONE; UREA
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00754247 ↗ | A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars | Completed | University of Miami | Phase 4 | 2006-03-01 | Keloids are thought to result from derailments in the typical wound healing process following cutaneous injury. Current treatment options for keloids include intralesional corticosteroids, silicone gel sheeting, compression, surgery and adjuvants to surgery, including radiation and cryotherapy. 0.5% hydrocortisone, silicone, vitamin E lotion (HSE) and onion extract gel (OE) are widely used over-the-counter medications for the treatment of keloids and hypertrophic scars. However, their efficacy and safety have not been compared in a blinded, placebo-controlled, prospective fashion. This study is being undertaken to determine the efficacy and safety of HSE versus OE versus placebo (Cetearyl alcohol; CEA) in subjects with hypertrophic scars and keloids. This is an investigator-blinded study, which means that the doctor evaluating you will not know if you are receiving the study medication or not. Another doctor will be supplying you with the medication and discussing any problems that you may have with the medication. You will be assigned to one of the three treatment groups: HSE, OE, or CEA. The group will be assigned by chance and you will have two in three chances of receiving treatment with a study medication, HSE or OE. The no treatment group will receive CEA, a bland lotion, containing no active ingredients such as steroids, silicone, vitamin E, or onion extract. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for HYDROCORTISONE; UREA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001409 ↗ | Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 1994-09-01 | Certain patients enrolled in NIH protocol 94-I-0206 at the Clinical Center may be eligible to participate in one or more of the following new options: - Donor/recipient extension phase - Both the recipient (HIV-infected twin) and donor (non-infected twin) will participate in this extension of the CD4-zeta gene therapy study. It will evaluate the safety and activity of infusing gene-modified CD4+ cells as well as the modified CD8+ cells. - Corticosteroid administration - A corticosteroid, such as prednisone, hydrocortisone or prednisolone, will be added to the interleukin-2 (IL-2) regimen for preventing or treating side effects of IL-2 such as fever and other flu-like symptoms. - Extended follow-up - A more intensive follow-up will be scheduled for patients with substantial numbers of lymphocytes that harbor the CD4-zeta gene. Every 3 months, participants will have blood tests and specialized tests of CD4 counts, HIV-1 viral load and numbers of circulating cells containing the CD4-zeta gene every 3 months> the frequency of follow-up visits may be reduced as time goes by. - IL-2 continuation - Participants will continue to receive periodic treatment with IL-2 to see how long the genetically modified cells persist in the bloodstream and to evaluate the long-term response to IL-2. - Home treatment with interleukin-2 - Participants may receive future IL-2 treatment cycles at home. Home treatment involves less frequent data and safety monitoring and no medical evaluations at the Clinical Center except at the beginning of each cycle. |
| NCT00001521 ↗ | Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia | Active, not recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 | 1995-06-08 |
This study was developed to determine if a combination of four drugs (flutamide,
testolactone, reduced hydrocortisone dose, and fludrocortisone) can normalize growth in
children with congenital adrenal hyperplasia.
The study will take 60 children, boys and girls and divide them into 2 groups based on the
medications given. Group one will receive the new four- drug combination. Group two will
receive the standard treatment for congenital adrenal hyperplasia (hydrocortisone and
fludrocortisone).
The boys in group one will take the medication until the age of 14 at which time they will
stop taking the four drug combination and begin receiving the standard treatment for
congenital adrenal hyperplasia. Girls in group one will take the four drug combination until
the age of 13, at which time they will stop and begin receiving the standard treatment for
congenital adrenal hyperplasia plus flutamide. Flutamide will be given to the girls until six
months after their first menstrual period.
All of the children will be followed until they reach their final adult height. The
effectiveness of the treatment will be determined by measuring the patient's adult height,
body mass index, and bone density. |
| NCT00002471 ↗ | Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 1990-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have acute B-lymphoblastic leukemia or recurrent non-Hodgkin's lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYDROCORTISONE; UREA
Condition Name
Clinical Trial Locations for HYDROCORTISONE; UREA
Trials by Country
Clinical Trial Progress for HYDROCORTISONE; UREA
Clinical Trial Phase
Clinical Trial Sponsors for HYDROCORTISONE; UREA
Sponsor Name
